Plasma-based treatment goes viral

Life-threatening viruses such as HIV, SARS, hepatitis and influenza, could soon be combatted in an unusual manner as researchers have demonstrated the effectiveness of plasma for inactivating and preventing the replication of adenoviruses.

When exposed to plasma - the fourth state of matter in addition to solids, liquids and gases - for a period of just 240 seconds, it was found that only one in a million viruses could still replicate - practically all were inactivated.

The study, published in IOP Publishing's Journal of Physics D: Applied Physics, is one of the first to concentrate specifically on viruses and builds on research that has already shown the usefulness of plasma in eradicating bacteria from skin and sterilising water.

Within a hospital environment, a plasma generating device could realistically rid hands of potentially lethal viruses that relay on a host organism to replicate and spread. In the long-term, plasma could be inhaled directly to treat viruses in the lungs, or applied to blood outside of the body to remove any viruses before transfusion.

The researchers, from the Max-Planck Institut für extraterrestrische Physik and Technische Universität München, specifically chose adenoviruses to examine as they are one of the most difficult viruses to inactivate. Illnesses resulting from this specific virus, for example, can only be managed by treating symptoms and complications of the infection, rather than targeting the actual virus itself.

Adenoviruses predominantly cause respiratory illnesses such as pneumonia and bronchitis and are hard to inactivate as the whole virus is encased in a protein layer, helping it to remain physically stable and tolerate moderate increases in heat and pH.

In this study, the adenoviruses were diluted to specific concentrations and then exposed to plasma for 240 seconds, before being incubated for an hour. A control group of adenoviruses were given the exact same treatment apart from the plasma exposure.

Two separate cell lines were then infected with the two sets of adenoviruses: the ones that were treated with plasma and the control group. To test whether a cell had the virus or not, the researchers programmed the virus to produce a protein that fluoresced green when a specific type of light was shone onto it.

Whilst the exact mechanisms behind the plasma's impressive effects are relatively unknown, it is thought that they are a result of a combination of reactions between the plasma and surrounding air, which create similar species to the ones found in our own immune system when under microbial attack.

The published version of the paper 'Effects of cold atmospheric plasmas on adenovirus in solution' (J L Zimmermann et al 2011 J. Phys. D: Appl. Phys. 44 505201) is freely available online from Wednesday 30 November at http://iopscience.iop.org/0022-3727/44/50/505201

Most Popular Now

Amgen and Allergan's MVASI™ (bevacizumab-awwb) and…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a bio...

Compound found in red wine opens door for new trea…

Like to unwind with a glass of red wine after a stressful day? Don't give alcohol all the credit. New research has revealed that the plant compound resveratrol, which is ...

HIV vaccine nears clinical trial following new fin…

A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar p...

Mylan and Upjohn, a division of Pfizer, to combine…

HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer's o...

Leading oncologists and nutritionists pinpoint are…

An international collaborative led by Ludwig Cancer Research and Cancer Research UK has identified key areas that are central to uncovering the complex relationship betwe...

Closing the door: breaking new ground related to a…

In order to sustain fast growth, cancer cells need to take up nutrients at a faster rate than healthy cells. The human glutamine transporter ASCT2 allows the amino acid g...

FDA approves first generics of Lyrica

On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associat...

Roche and Spark Therapeutics, Inc. announce extens…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") announced that Roche has extended the offering period of its previously announced...

FDA approves first treatment for severe hypoglycem…

The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that c...

Rye is healthy, thanks to an interplay of microbes

Eating rye comes with a variety of health benefits. A new study from the University of Eastern Finland now shows that both lactic acid bacteria and gut bacteria contribut...

GSK completes transaction with Pfizer to form new …

The Joint Venture brings together two highly complementary portfolios of trusted consumer health brands, including GSK's Sensodyne, Voltaren and Panadol and Pfizer's Advi...

Eating more plant-based foods may be linked to bet…

Eating mostly plant-based foods and fewer animal-based foods may be linked to better heart health and a lower risk of dying from a heart attack, stroke or other cardiovas...